Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: HIV/AIDS Bridge Funding - Biomedical/Clinical Stream

Ottawa Hospital Research Institute

$100,000.00

Regulation and Function of Soluble IL-7 Receptor Alpha (CD127) in HIV Infection

EF 2010-11

Résumé
Impaired cytotoxic T-cell (CTL) activity and altered thymic function likely contribute to progression of HIV disease but the reasons for this remain to be established. Interleukin (IL)-7 signaling is essential for both CTL and thymic function and recent findings in our laboratory implicate a role for the regulation of the IL-7 receptor alpha (CD127) in the immunopathogenesis of HIV infection. We have shown that a soluble form of CD127 (sCD127) is released by CD8+ T-cells and demonstrated that sCD127 can inhibit IL-7 activity in vitro. In addition, we have detected sCD127 in human plasma and found that it is increased in HIV infection. The proposed work will investigate the mechanism(s) by which sCD127 is released by CD8+ T-cells and thymocytes and its role in HIV infection in vitro. We will also examine the whether SIV infection of rhesus macaque monkeys (a model of HIV infection), antiretroviral therapy of infected animals and/or IL-7 therapy influence the expression of sCD127. Lastly, we evaluate the functional role of sCD127 in vivo using a mouse model of Listeria monocytogenes infection, experiments that will logically lead to further in vivo experiments that model HIV infection. Regulation and/or function of sCD127 may be important in explaining HIV-associated immune dysfunction and, if so, determining the mechanism(s) involved will lead to a better understanding of HIV immunopathogenesis and may lead to the development of novel immune-based therapies.
Programme
Operating Grant - PA: HIV/AIDS Bridge Funding - Biomedical/Clinical Stream
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
223192
Name
Angel Jonathan B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
Regulation and Function of Soluble IL-7 Receptor Alpha (CD127) in HIV Infection
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: HIV/AIDS Bridge Funding - Biomedical/Clinical Stream
Keyworddelim
Cd8+ T-Cells; Flow Cytometry; Gamma Chain Cytokines; Hiv Immunopathogenesis; Il-7 Receptor; Luminex; Murine Model Of Lcmv; Siv Infection; Thymocytes; Western Blot
Abstract
Impaired cytotoxic T-cell (CTL) activity and altered thymic function likely contribute to progression of HIV disease but the reasons for this remain to be established. Interleukin (IL)-7 signaling is essential for both CTL and thymic function and recent findings in our laboratory implicate a role for the regulation of the IL-7 receptor alpha (CD127) in the immunopathogenesis of HIV infection. We have shown that a soluble form of CD127 (sCD127) is released by CD8+ T-cells and demonstrated that sCD127 can inhibit IL-7 activity in vitro. In addition, we have detected sCD127 in human plasma and found that it is increased in HIV infection. The proposed work will investigate the mechanism(s) by which sCD127 is released by CD8+ T-cells and thymocytes and its role in HIV infection in vitro. We will also examine the whether SIV infection of rhesus macaque monkeys (a model of HIV infection), antiretroviral therapy of infected animals and/or IL-7 therapy influence the expression of sCD127. Lastly, we evaluate the functional role of sCD127 in vivo using a mouse model of Listeria monocytogenes infection, experiments that will logically lead to further in vivo experiments that model HIV infection. Regulation and/or function of sCD127 may be important in explaining HIV-associated immune dysfunction and, if so, determining the mechanism(s) involved will lead to a better understanding of HIV immunopathogenesis and may lead to the development of novel immune-based therapies.
Competitiondate
201009
Approvedterm2
1 yr 0 mth
Pinamesdelim
Angel, Jonathan B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~